Open an account

ENDRA Life Sciences

NDRA · NASDAQ

$4.47−$0.28 (−5.89%)TodayMarket closed ·
Prev close $4.75

About NDRA

ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 11 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

Employees
11
Headquarters
Ann Arbor, Michigan
Listed
Jun 28, 2017
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
endrainc.com

NDRA key statistics

Market cap
6.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
23.66K
Volume
20.33K
Open price
$4.61
High today
$5.00
Low today
$4.26
52 Week high
$6.90
52 Week low
$2.96

ENDRA Life Sciences (NDRA) at a glance

ENDRA Life Sciences (NDRA) last traded at $4.47, with a market cap of 6.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.26 and $5.00. The current price is 4.9% above the day's low and 10.5% below its high.

Volume so far is 20.33K shares, in line with the average of 23.66K shares a day.

Over the past year ENDRA Life Sciences has ranged from $2.96 to $6.90, and now sits 38% of the way up that range.

ENDRA Life Sciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.06 per share against an estimate of -$0.8568.

The average analyst price target is $25.50, 470.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $25.50
Low
$25.25
Now
$4.47
High
$26.25

NDRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 67.9% on average.

  1. Q3 FY24: reported -$9.54 per share against an estimate of -$63.55
  2. Q4 FY24: reported -$7.69 per share against an estimate of -$4.18
  3. Q1 FY25: reported -$1.86 per share against an estimate of -$3.99
  4. Q2 FY25: reported -$1.71 per share against an estimate of -$2.32
  5. Q3 FY25: reported -$2.10 per share against an estimate of -$1.99
  6. Q4 FY25: reported -$3.26 per share against an estimate of -$1.25
  7. Q1 FY26: reported -$1.80 per share against an estimate of -$1.25
  8. Q2 FY26: reported $0.06 per share against an estimate of -$0.8568

NDRA news

  • Press releaseBusiness Wire

    ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    ASP Isotopes Issues Letter to Shareholders

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--FSRL, SYNA, TECH, and NDRA

  • Press releaseBusiness Wire

    NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders

  • Press releaseBusiness Wire

    ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

  • Press releaseBusiness Wire

    ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

  • Press releaseBusiness Wire

    ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as ENDRA Life Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.